GeoVax Shares Surge After Cancer Vaccine Patent In US

GeoVax Labs Inc GOVX has received a U.S. patent covering its vector platform for expressing tumor-associated antigens in virus-like particles (VLPs).
The platform comes from a Modified Vaccinia Ankara (MVA) viral vector and encompasses GeoVax's Mucin 1 (MUC1) tumor-associated antigen immunotherapy candidate.
GeoVax's initial results with its MVA-VLP-MUC1 immunotherapy candidates have been encouraging.
David Dodd, GeoVax President, and CEO commented, "This patent allowance adds to our growing portfolio of wholly-owned, co-owned, and in-licensed intellectual property, which now stands at over 70 granted or pending patent applications spread over 20 patent families."
Related Link: GeoVax Labs In-Licenses Development Rights To Multi-Antigenic COVID-19 Vaccine Candidate.
Price Action: GOVX shares are 19.70% at $4.62 during the market session on the last check Tuesday.